Developmental Funds

在本项目期间，CCSG开发资金被高效和富有成效地用于 招募新研究人员，建立有价值的新共享资源，资助有限数量的及时试点 项目，为有前途的研究人员提供临时支持，并为开发新的 癌症的分子诊断方法。在新招聘的四名YCC教职员工中，有三名留了下来 YCC成员，所有成员都是NCI资助的。其中一名招聘的教职员工目前担任联合负责人 免疫学和免疫疗法研究项目。另一名受支持的教职员工领导癌症 预防和控制研究计划(PCRP)的控制部分。三分之一的人已经成了大四学生 PCRP的领导者和关键技术广泛使用的组织分析模块的负责人 组织服务共享资源。临时资金的接受者已获得国际认可 她的新书研究了核糖体生物发生的失调作为一种广泛的 恶性肿瘤。她现在是YCC基础科学的领导者，有多个项目间的合作。 为定义全基因组甲基化状态的高度创新计划提供的资金导致了一种 有可能成为癌症分子诊断的有力方法。在目前的申请中，YCC提出了一个 更有针对性地使用大多数已分配的发展资金，以进一步发展八个公认的 有针对性的卓越研究领域(TARE)，并建立四个创新的共享资源，需要 这些皮毛的支持。科学指导委员会，YCC主任，高级领导团队，以及 研究计划负责人已经确定了这些目标领域，因为它们每个都涉及到 已建立的研究项目，源自多个YCC研究计划，并通过共同的 研究主题和核心服务使用情况。目标是促进和加快这些技术的成熟 与孢子或计划项目同行评审资金之间的协同互动，以 青年会。由于这些研究项目与临床和基础科学家在持续生产方面相匹配 协作，他们有极好的机会演变为成功的翻译应用程序和新的 临床试验。还要求提供支助，以补充为四个开发共享的机构提供的资金 开展TARE项目所需的资源，并支持越来越多的调查人员启动 临床试验。

During the current project period, CCSG Developmental Funds were efficiently and productively used to recruit new researchers, establish a valuable new Shared Resource, fund a limited number of timely pilot projects, provide interim support to a promising investigator, and provide support for development of a novel method for the molecular diagnosis of cancer. Of the four new YCC faculty members recruited, three remain YCC members, and all are NCI-funded. One of the recruited faculty members currently serves as a Co-Leader of the Immunology & Immunotherapy Research Program. Another supported faculty recruit leads the Cancer Control component of the Prevention & Control Research Program (PCRP). A third has become a senior leader in the PCRP and Director of the widely used Tissue Analysis module of the Critical Technologies Tissue Services Shared Resource. The recipient of interim funding has received international recognition for her novel studies on dysregulation of ribosome biogenesis as a predisposing factor to a wide range of malignancies. She is now a YCC basic science leader, with multiple inter-programmatic collaborations. Funding for a highly innovative plan to define genome-wide methylation status has led to the development of a potentially powerful method for the molecular diagnosis of cancer. In the current application, YCC proposes a more focused use of the majority of the allotted Developmental Funds, to further develop eight recognized targeted areas of research excellence (TARE) and to establish four innovative Shared Resources required for the support of these TARE. The Scientific Steering Committee, YCC Director, Senior Leadership Team, and Research Program Leaders have identified these targeted areas, since they each involve groups of established research projects, emanating from multiple YCC Research Programs, and are linked by common research themes and core service usage. The goal is to facilitate and expedite the maturation of these synergistic interprogrammatic interactions into SPORE or program project peer-reviewed funding, anchored in the YCC. Since these research projects match clinical and basic scientists in on-going productive collaborations, they have excellent chances to evolve into successful translational applications and new clinical trials. Support is also requested to supplement institutional funding for four developing Shared Resources, required for conduct of the TARE projects and to support the expanding number of investigatorinitiated clinical trials.